Europe has money, human resources and a basic-science base that produces world-leading cancer research. Why, then, aren’t these assets being translated into clinical advances?
Translating good science into new treatments
Hannah Brown
Related Articles
Impact Factor
Dropping bars or rising hoops phase III outcomes of NSCLC
Editorial
When the trial you need is just over the border
Drug Watch